Novo Nordisk appoints new general manager to drive healthcare strategy

Novo Nordisk Ireland has named Dilek Dogan Gurluk as its new General Manager, ushering in a strategic shift to strengthen chronic disease and obesity management across the country. Gurluk brings more than two decades of global pharmaceutical expertise, having held senior leadership roles across Europe, the Middle East, Asia Pacific, and Turkey.

Her appointment aligns with the company’s A Healthier Ireland Strategy, a multifaceted initiative that fosters collaboration with healthcare providers, government agencies, and community partners to tackle chronic conditions holistically. Gurluk emphasises that effective disease management requires more than medicine alone, advocating a societal approach that combines innovation, science, and systemic engagement.

With prior experience as Senior Marketing Director at Novo Nordisk Netherlands, she has a demonstrated record in brand commercialisation and leadership development. Under her guidance, Novo Nordisk Ireland aims to reinforce its legacy in diabetes care while extending its impact on obesity treatment, building high-performing teams capable of executing transformative healthcare initiatives.

Her educational background includes a Bachelor’s degree in Political Science and International Relations and an Executive MBA, equipping her with the strategic and operational acumen necessary to scale organisational impact. The appointment reflects Novo Nordisk’s ongoing investment in leadership talent that can navigate complex healthcare challenges while driving measurable outcomes for patients and society alike.

Discover how Gurluk’s leadership is set to reshape healthcare strategy in Ireland by exploring the full story.